{"ticker": {"uuid": "49ae998b-b99e-4778-afa8-ddeb753bfb11", "symbol": "KRRO", "name": "Korro Bio, Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Korro Bio, Inc. announced the grant of non-statutory stock options to seven newly hired employees as an inducement to employment. These grants, approved by Korro\u2019s independent Compensation Committee, were made under Korro\u2019s 2026 Inducement Plan in accordance with Nasdaq Listing R", "url": "https://www.manilatimes.net/2026/07/11/tmt-newswire/globenewswire/korro-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4/2382608", "source_name": "The Manila Times", "published_at": "2026-07-11T06:10:27", "published_display": "11 Jul 2026 06:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Korro Bio, Inc. \u2013 NASDAQ:KRRO", "summary": "This article provides a financial metric\u2014the price to sales forward\u2014for Korro Bio, Inc. (NASDAQ: KRRO). It indicates the company's ticker, the exchange it trades on, and that the market is currently closed. The content itself seems to be a placeholder or a partial display from a ", "url": "https://www.tradingview.com/symbols/NASDAQ-KRRO/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T05:13:14", "published_display": "09 Jul 2026 05:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Korro Bio, Inc. \u2013 NASDAQ:KRRO", "summary": "This article provides financial information for Korro Bio, Inc. (NASDAQ: KRRO), specifically focusing on its forward price-to-earnings ratio. It is a data-focused piece from TradingView, indicating that the market is closed and no trades have occurred for the stock.", "url": "https://www.tradingview.com/symbols/NASDAQ-KRRO/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T00:41:52", "published_display": "09 Jul 2026 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korro Bio: Why Director Sales Temper a 'Strong Buy' Consensus", "summary": "Korro Bio, a biopharmaceutical company specializing in RNA editing, faces conflicting signals, with director Jean Francois Formela's affiliated funds selling over $4 million in stock despite a \"Strong Buy\" consensus from Wall Street analysts. The company's innovative pipeline and", "url": "https://www.kavout.com/market-lens/korro-bio-why-director-sales-temper-a-strong-buy-consensus", "source_name": "Kavout | AI", "published_at": "2026-07-08T17:41:52", "published_display": "08 Jul 2026 17:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korro Bio director Formela sells $1.54m in shares By Investing.com", "summary": "Korro Bio director Jean Francois Formela sold approximately $1.54 million worth of the company's common stock in early July through a Rule 10b5-1 trading plan. These sales occurred on July 2 and July 6, 2026, at weighted average prices between $13.96 and $14.03, following a 71% s", "url": "https://ng.investing.com/news/stock-market-news/korro-bio-director-formela-sells-154m-in-shares-93CH-2590016", "source_name": "Investing.com Nigeria", "published_at": "2026-07-08T17:41:52", "published_display": "08 Jul 2026 17:41", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korro Bio, Inc. (KRRO) Upgraded to Buy: What Does It Mean for the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOeW8yYXQyb05JSWJncmczT1VvX2ZyNl9qUjdPenNBanFLaHlJR0F5bVlXR001RHRKcWhVUjFrZVVpVXJtN1N6MU1YcW1zX0JtWGozZUN2RDVVWTlWY0xCYTN3WnVBSU9qUHpoTURuT2M3aFcxZ3plMGtYSXYxTmNMMzd5aTlKV1pxVW1MNFI5dzNpZlJKVUxN?oc=5", "source_name": "Market source", "published_at": "2026-07-08T16:00:03+00:00", "published_display": "08 Jul 2026 16:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korro Bio Insider Sold Shares Worth $1,542,970, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/korro-bio-insider-sold-shares-080624636.html", "source_name": "MT Newswires", "published_at": "2026-07-08T08:06:24+00:00", "published_display": "08 Jul 2026 08:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korro Bio director Formela sells $1.54m in shares", "summary": "Korro Bio director Jean Francois Formela sold approximately $1.54 million worth of shares in early July through a pre-arranged trading plan. These sales occurred after KRRO shares saw a 71% surge over the past six months and coincide with recent analyst upgrades and new pipeline ", "url": "https://www.investing.com/news/insider-trading-news/korro-bio-director-formela-sells-154m-in-shares-93CH-4780443", "source_name": "Investing.com", "published_at": "2026-07-08T07:09:55", "published_display": "08 Jul 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Korro Bio Inc For: 7 July By Investing.com", "summary": "This article announces that Korro Bio Inc. (KRRO) filed a Form 4 for July 7th. A Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the beneficial ownership position of company insiders. The article does no", "url": "https://ca.investing.com/news/stock-market-news/form-4-korro-bio-inc-for-7-july-93CH-4724149", "source_name": "Investing.com Canada", "published_at": "2026-07-07T22:10:25", "published_display": "07 Jul 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Korro Bio For: 6 July By Investing.com", "summary": "This article announces the filing of Form 144 for Korro Bio on July 6th. It briefly mentions the company's stock symbol KRRO and its current performance while providing no further details about the filing itself. The article also includes various market data and other news headli", "url": "https://ca.investing.com/news/stock-market-news/form-144-korro-bio-for-6-july-93CH-4721891", "source_name": "Investing.com Canada", "published_at": "2026-07-07T04:10:30", "published_display": "07 Jul 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korro Bio, Inc. (KRRO) soars 17.6%: Is further upside left in the stock?", "summary": "Korro Bio, Inc. (KRRO) experienced a significant 17.6% surge in its stock price, raising questions about its future growth potential. This movement comes amid broader market trends and the company's recent performance. Investors are now evaluating whether this momentum suggests f", "url": "https://www.msn.com/en-us/health/other/korro-bio-inc-krro-soars-17-6-is-further-upside-left-in-the-stock/ar-AA263PQJ", "source_name": "MSN", "published_at": "2026-07-06T05:40:30", "published_display": "06 Jul 2026 05:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KRRO - Korro Bio Inc Options", "summary": "This article provides a detailed financial overview of Korro Bio Inc (KRRO), including its last close price, market capitalization, income, sales, and various financial ratios. It also lists key performance metrics like insider ownership, institutional ownership, profitability, a", "url": "https://finviz.com/stock?t=KRRO&ta=1&p=d&ty=oc&b=2&r=m1&ov=chain_strike&s=12.5", "source_name": "Finviz", "published_at": "2026-07-04T03:40:50", "published_display": "04 Jul 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korro Bio, Inc.(NasdaqCM: KRRO) added to Russell 2500 Growth Benchmark", "summary": "Korro Bio, Inc. (NasdaqCM: KRRO) has been added to the Russell 2500 Growth Benchmark index. The company specializes in developing genetic medicines based on RNA editing, focusing on diseases like Alpha-1 Antitrypsin Deficiency. Recent news for Korro Bio includes additions to seve", "url": "https://www.marketscreener.com/news/korro-bio-inc-nasdaqcm-krro-added-to-russell-2500-growth-benchmark-ce7f5fdfdd88f322", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T15:57:00", "published_display": "29 Jun 2026 15:57", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korro Bio, Inc.(NasdaqCM: KRRO) added to Russell Microcap Growth Benchmark Index", "summary": "Korro Bio, Inc. (NasdaqCM: KRRO) has been included in the Russell Microcap Growth Benchmark Index. This announcement highlights the company's growing presence in the financial markets. The biopharmaceutical company focuses on developing genetic medicines based on RNA editing for ", "url": "https://www.marketscreener.com/news/korro-bio-inc-nasdaqcm-krro-added-to-russell-microcap-growth-benchmark-index-ce7f5fded08bff23", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T12:42:43", "published_display": "29 Jun 2026 12:42", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korro Bio, Inc.(NasdaqCM: KRRO) added to Russell 3000E Growth Benchmark", "summary": "Korro Bio, Inc. (NasdaqCM: KRRO), a clinical-stage biopharmaceutical company focused on RNA editing for genetic medicines, has been added to the Russell 3000E Growth Benchmark. The company's lead development candidate, KRRO-110, aims to treat Alpha-1 Antitrypsin Deficiency (AATD)", "url": "https://www.marketscreener.com/news/korro-bio-inc-nasdaqcm-krro-added-to-russell-3000e-growth-benchmark-ce7f5fdedf8bff27", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T04:52:00", "published_display": "29 Jun 2026 04:52", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korro Bio, Inc. Actuals & Estimates (NASDAQ:KRRO)", "summary": "This article provides an overview of Korro Bio, Inc. (NASDAQ: KRRO) stock performance, analyst estimates, and financial data. It covers current stock price, historical highs and lows, market capitalization, upcoming earnings dates, and past financial results like revenue and net ", "url": "https://www.tradingview.com/symbols/NASDAQ-KRRO/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-26T00:09:51", "published_display": "26 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KRRO Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Korro Bio, Inc. (KRRO) stock, including analyst price targets, past performance, and key financial data. According to analysts, KRRO has a max estimate of $30.00 and a min estimate of $8.00. The company's current stock price is $12.17, and it ", "url": "https://www.tradingview.com/symbols/NASDAQ-KRRO/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T17:09:51", "published_display": "25 Jun 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atlas Venture sells KRRO common stock in late May\u2013June 2026 (KRRO)", "summary": "Atlas Venture entities recently filed Rule 144 notices detailing proposed and executed sales of Korro Bio, Inc. (KRRO) common stock in May and June 2026. The filings show multiple transactions, including significant sales on June 22 and June 23, 2026, by Atlas Venture Fund XI, L.", "url": "https://www.stocktitan.net/sec-filings/KRRO/144-korro-bio-inc-sec-filing-a3df7f1314ff.html", "source_name": "Stock Titan", "published_at": "2026-06-25T13:42:43", "published_display": "25 Jun 2026 13:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atlas Venture (KRRO) sells 101,579 shares on 06/23/2026, multiple Form 144 entries", "summary": "Korro Bio, Inc. (KRRO) reported multiple sales of its common stock by affiliated holders, Atlas Venture Fund XI, L.P. and Atlas Venture Opportunity Fund II, L.P., through Form 144 filings. The largest listed sale was for 101,579 shares on June 23, 2026, totaling $1,447,785.17. Ot", "url": "https://www.stocktitan.net/sec-filings/KRRO/144-korro-bio-inc-sec-filing-ea3d508274d5.html", "source_name": "Stock Titan", "published_at": "2026-06-25T13:09:55", "published_display": "25 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Korro Bio Inc For: 24 June By Investing.com", "summary": "This article from Investing.com is a regulatory filing update for Korro Bio Inc. It specifically mentions a \"Form 4\" filing dated June 24 and attributes the information to Reuters. The article itself is very brief, serving primarily as a notification about this financial document", "url": "https://au.investing.com/news/stock-market-news/form-4-korro-bio-inc-for-24-june-93CH-4503661", "source_name": "Investing.com Australia", "published_at": "2026-06-25T12:09:51", "published_display": "25 Jun 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korro Bio Insider Sold Shares Worth $2,458,582, According to a Recent SEC Filing", "summary": "An insider at Korro Bio sold shares valued at $2,458,582, as disclosed in a recent SEC filing. The company is a clinical-stage biopharmaceutical firm focused on developing genetic medicines based on RNA editing for both rare and common diseases. Korro Bio's stock performance and ", "url": "https://www.marketscreener.com/news/korro-bio-insider-sold-shares-worth-2-458-582-according-to-a-recent-sec-filing-ce7f5fd8da8ef22d", "source_name": "www.marketscreener.com", "published_at": "2026-06-25T12:09:51", "published_display": "25 Jun 2026 12:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korro Bio director Jean Francois Formela sells $2.45m in shares", "summary": "Korro Bio director Jean Francois Formela sold approximately $2.46 million in company shares across three trading days in late June 2026, executed under a Rule 10b5-1 trading plan. The sales occurred as the stock traded between $13.95 and $14.98, with the current price reflecting ", "url": "https://www.investing.com/news/insider-trading-news/korro-bio-director-jean-francois-formela-sells-245m-in-shares-93CH-4759506", "source_name": "Investing.com", "published_at": "2026-06-25T01:39:53", "published_display": "25 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korro Bio (KRRO) director-affiliated Atlas funds sell 171K shares under 10b5-1 plan", "summary": "Funds affiliated with Korro Bio director Jean Francois Formela, specifically Atlas Venture entities, sold a total of 171,405 shares of Korro Bio common stock through eight open-market transactions. These sales, executed under a pre-arranged Rule 10b5-1 trading plan adopted on Apr", "url": "https://www.stocktitan.net/sec-filings/KRRO/form-4-korro-bio-inc-insider-trading-activity-2201a3e01db5.html", "source_name": "Stock Titan", "published_at": "2026-06-25T01:10:55", "published_display": "25 Jun 2026 01:10", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Korro Bio For: 23 June By Investing.com", "summary": "This article from Investing.com announces the filing of Form 144 for Korro Bio on June 23. It provides limited textual content but is surrounded by extensive financial market data, including various indices, commodity prices, and stock performances. The core message is a direct r", "url": "https://ca.investing.com/news/stock-market-news/form-144-korro-bio-for-23-june-93CH-4704369", "source_name": "Investing.com Canada", "published_at": "2026-06-23T22:20:00", "published_display": "23 Jun 2026 22:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atlas Venture sells KRRO (KRRO) stock \u2014 2,441 and 419 shares reported", "summary": "Atlas Venture has filed a Form 144, indicating proposed sales of Korro Bio, Inc. (KRRO) common stock. Atlas Venture Fund XI intends to sell 2,441 shares for $34,051.95, and Atlas Venture Opportunity Fund II plans to sell 419 shares for $5,845.05, with both sales dated May 28, 202", "url": "https://www.stocktitan.net/sec-filings/KRRO/144-korro-bio-inc-sec-filing-87cae4bbc560.html", "source_name": "Stock Titan", "published_at": "2026-06-23T01:09:21", "published_display": "23 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Korro Bio For: 22 June By Investing.com", "summary": "This article announces the filing of Form 144 for Korro Bio on June 22nd, as reported by Investing.com. It is a brief, technical notification, typical of financial news outlets reporting on regulatory filings. The article also includes stock market data and other news headlines.", "url": "https://ca.investing.com/news/stock-market-news/form-144-korro-bio-for-22-june-93CH-4702061", "source_name": "Investing.com Canada", "published_at": "2026-06-22T21:42:18", "published_display": "22 Jun 2026 21:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korro Bio Inc (KRRO) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "Korro Bio Inc (KRRO) currently holds a price momentum score of 6.96, placing it 183rd in the Biotechnology & Medical Research industry. The stock is trading between resistance at $14.69 and support at $10.58, indicating potential for range-bound swing trading. Technical indicator", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-krro/technical", "source_name": "TradingKey", "published_at": "2026-06-18T22:09:31", "published_display": "18 Jun 2026 22:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Korro Bio (NASDAQ:KRRO) Spend Its Cash Wisely?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korro Bio: RNA Editor Plots Way Back After AATD Study Fail - I'm Holding (NASDAQ:KRRO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPdGlCOHp3dmRfeU9YYWpValZnR1hsdEtBaXptQjhXRVpzMDc4VngxVkctY19HaXZBMEpvdl82S1FPQlBnc09jakxjeFpPX01QQnh4aW5LWW5lc0Z3UDNsLW5CcE5sZV81ZHNzaGxXRHk4ZGhoNm9tcVJwMTJzcWl6UWVTeURfN0xqSmhUNHFNSVlkQ0hCT2o1aEJwWktZSGJ6ZG9vMVpyNl9VdjY0?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "One Korro Bio Insider Raised Stake By 19% In Previous Year", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNVnBZN0JvdHJvMVNBNFFkUDJhYjRmX0QtV1JkV1RIcGtSVjNGUFNYcVU3THZtcjZ5cFZ0ODdDdTdwRk1tbjZBVmFES09jUXFQTnhVbS1UWlpsc3g3RTBfSFpZckMxeGc3RjhYWUJXRWZHeU16X2s0aDlaVl9vdU5kdENzVnZ4MFNuSkdoU3RUcnJJTHA3ak96bw?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korro Bio CEO Ram Aiyar sells $196,672 in company stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQeEJxZU93a3VJYXpqMVpHYXA2cU80b1JhblAwSEpDRG82VVNRMkNpTEJ0ZnNNTFJud0Y0alhxMGlRU19Rd3QtZUExWVJBU3kzUURidEZyOWdFOWswSkxyWmo2djRsN2Q1WEJjUWhRRmx3ZC16ZXQ4T01GYy03bGYtTUtRWGVXR0F6aVF5eVcxS095SW1XV3U5V0NkUEhFUmJzYmlVbzd0ckVPWVl1THFCY3BDWGxkQmxOS2c?oc=5", "source_name": "Investing.com", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korro to Present at the 2026 Jefferies Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/korro-present-2026-jefferies-global-110000963.html", "source_name": "GlobeNewswire", "published_at": "2026-05-27T11:00:00+00:00", "published_display": "27 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/korro-selects-krro-111-development-110000039.html", "source_name": "GlobeNewswire", "published_at": "2026-05-19T11:00:00+00:00", "published_display": "19 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citigroup Initiates Korro Bio at Buy With $21 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/citigroup-initiates-korro-bio-buy-113925505.html", "source_name": "MT Newswires", "published_at": "2026-05-18T11:39:25+00:00", "published_display": "18 May 2026 11:39", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "What Makes Korro Bio, Inc. (KRRO) a New Buy Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxNcm5ucjVsNDc0bVY0cl9UanNGcDVvXzdWR3hyR3pvVTVadElwSTVEMXctT1M4Tl83NHhDem5MZ2pkR29ld09aVzVveUJUdEVaTzhJSDJ6ekwySlR3TEtsX1l2eGhOMnZsUk0yRWh1ekpQQWIwdEo5ampMQjByUVhiMmVrcTV6MjhqYTRPWDBtMmNOY3c?oc=5", "source_name": "Market source", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Investors pour $85M into RNA editor Korro Bio\u2019s genetic disease drugs", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOY3gwamxGdDhtekx2eElRdVhpN2V0UjZuVE9IckdBd1VLY1R0RG92SWtOaFp4RENhd19sbDA4cWVnS3IyazJnQ3hmd1ZJUF9pNi1rRE5rTU9nWWxVSXJfN01wSi1Ub1dWSFNqdTRGVlFmeHFUQmdqQXFPYUttV2VScENObGtpTUtxaUt6SFh3QXlHRFBuNkxFUm5ObTdOZjA5bElVblhwQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korro Announces $85 Million Private Placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxPNG5YTWNheGd2NmtWd3dfUDdqVUNCRi1ScEFKYUtUdTFOcWdYMUF5RUlUMTYwZ2ZRc1NDeTF2QmtnWnBzZlZCRXlla2xZUkpUQ3BBenhxZE9JNkR5R29BZjRxblVIbXk3QlY3UDFHUl9BaWFuNmhsbzI2NzBQT28xZDlnSHFqT0ljcVBz?oc=5", "source_name": "citybiz", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Think Korro Bio (NASDAQ:KRRO) Needs To Drive Business Growth Carefully", "summary": "", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTE0tbWJuYXNnSnR0N29CMzFPUU9xYzNxR1VWZGtBVUlYX0JRX0JLUnR1UFpCdmJ5OV95elIxaU93eXA3NHctUzJ4WlUyNU9VVDJEUkhzekZwdUM4NHVoeFhlTHVWaU0zckdfWktmVjNrSUVYNlIxZXhxWTlEZWduQQ?oc=5", "source_name": "Market source", "published_at": "2026-02-13T08:00:00+00:00", "published_display": "13 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "StockWatch: Korro Craters 81% on Data; Patient Death Sours Analysts on Intellia", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOQ2o1RGhNWXdZNGRISk51aEIyT0s2QWF1dXFkcjZNLXNKdWJ0Y2YzMGxGNnllQUQ1R1ljcjlScWZKMUdJdDEtaFJpNnVHdy1wQzdrekxiR1J2TklJcVVSa3lGUHhIRmR2V1YyZ0FGdE1PaGszdW10Rko2eVJFOHZwUmgta0JVOXgyLUxIQVVrcXQydU1uUXBvUXBzZzJPWTIyeXJ6QV9EYUwyV1g5NTVCRVl0dms1aEs3RTZEREo3S0RaMUNQ?oc=5", "source_name": "Genetic Engineering and Biotechnology News", "published_at": "2025-11-16T08:00:00+00:00", "published_display": "16 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korro Suffers Cacophony of Bad News as Lead Candidate Fails, Novo Pauses RNA Deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNMlZmTTJISHREZktJQ1JQMlh1Sl9rQmY4UjBLWl9CdW5PT001eHpOWHMyMDY5akVfX1VQME5mTDAyRktXQmhmQldpTm4wOHNlVG51MkVjLWlxTkhPMFhoMmNwQi1SQXMyMjZMX196cnl0MThoS21MWWxTdmVFdFprVjJOTFlFT0xkaHpsczEzaFJESG9Ra0lYeGEtYmwweDZESm5iSmxsN0ZSX0tCaVg5bjJha3FHODdlREJYQ0ZfVQ?oc=5", "source_name": "BioSpace", "published_at": "2025-11-13T08:00:00+00:00", "published_display": "13 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Korro Bio, Inc. (KRRO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE1tckc3WngyZmhfUjVnR05kelh6RGlLM0k0NUt0Y01jSkk2dEptb1RndlhRdlZINFBYWnR0TDBSREYxazVYdDBMZURKbU04SlhoTUtTMURIX3B5WmxwNmdQTHNENGhzT1l0WnozMg?oc=5", "source_name": "Zacks Investment Research", "published_at": "2024-04-25T01:06:05+00:00", "published_display": "25 Apr 2024 01:06", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korro Bio Inc (KRRO) News, Articles, Events & Latest Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTE8xX0dkY0ZFdHNabG0zN213a1JqS1VldWMzVXFtMzRJVnNYMzlZeWxaOEZYRlRCaGtfTGI4b1hESm5tc1I1a3lQU2h4LXNQY1Nu?oc=5", "source_name": "Stocktwits", "published_at": "2023-11-09T02:32:26+00:00", "published_display": "09 Nov 2023 02:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Korro Bio, Inc. announced the grant of non-statutory stock options to seven newly hired employees as an inducement to employment. These grants, approved by Korro\u2019s independent Compensation Committee, were made under Korro\u2019s 2026 Inducement Plan in accordance with Nasdaq Listing R", "url": "https://www.manilatimes.net/2026/07/11/tmt-newswire/globenewswire/korro-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4/2382608", "source_name": "The Manila Times", "published_at": "2026-07-11T06:10:27", "published_display": "11 Jul 2026 06:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Korro Bio, Inc. \u2013 NASDAQ:KRRO", "summary": "This article provides a financial metric\u2014the price to sales forward\u2014for Korro Bio, Inc. (NASDAQ: KRRO). It indicates the company's ticker, the exchange it trades on, and that the market is currently closed. The content itself seems to be a placeholder or a partial display from a ", "url": "https://www.tradingview.com/symbols/NASDAQ-KRRO/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T05:13:14", "published_display": "09 Jul 2026 05:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Korro Bio, Inc. \u2013 NASDAQ:KRRO", "summary": "This article provides financial information for Korro Bio, Inc. (NASDAQ: KRRO), specifically focusing on its forward price-to-earnings ratio. It is a data-focused piece from TradingView, indicating that the market is closed and no trades have occurred for the stock.", "url": "https://www.tradingview.com/symbols/NASDAQ-KRRO/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T00:41:52", "published_display": "09 Jul 2026 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korro Bio: Why Director Sales Temper a 'Strong Buy' Consensus", "summary": "Korro Bio, a biopharmaceutical company specializing in RNA editing, faces conflicting signals, with director Jean Francois Formela's affiliated funds selling over $4 million in stock despite a \"Strong Buy\" consensus from Wall Street analysts. The company's innovative pipeline and", "url": "https://www.kavout.com/market-lens/korro-bio-why-director-sales-temper-a-strong-buy-consensus", "source_name": "Kavout | AI", "published_at": "2026-07-08T17:41:52", "published_display": "08 Jul 2026 17:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korro Bio director Formela sells $1.54m in shares By Investing.com", "summary": "Korro Bio director Jean Francois Formela sold approximately $1.54 million worth of the company's common stock in early July through a Rule 10b5-1 trading plan. These sales occurred on July 2 and July 6, 2026, at weighted average prices between $13.96 and $14.03, following a 71% s", "url": "https://ng.investing.com/news/stock-market-news/korro-bio-director-formela-sells-154m-in-shares-93CH-2590016", "source_name": "Investing.com Nigeria", "published_at": "2026-07-08T17:41:52", "published_display": "08 Jul 2026 17:41", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korro Bio, Inc. (KRRO) Upgraded to Buy: What Does It Mean for the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOeW8yYXQyb05JSWJncmczT1VvX2ZyNl9qUjdPenNBanFLaHlJR0F5bVlXR001RHRKcWhVUjFrZVVpVXJtN1N6MU1YcW1zX0JtWGozZUN2RDVVWTlWY0xCYTN3WnVBSU9qUHpoTURuT2M3aFcxZ3plMGtYSXYxTmNMMzd5aTlKV1pxVW1MNFI5dzNpZlJKVUxN?oc=5", "source_name": "Market source", "published_at": "2026-07-08T16:00:03+00:00", "published_display": "08 Jul 2026 16:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korro Bio Insider Sold Shares Worth $1,542,970, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/korro-bio-insider-sold-shares-080624636.html", "source_name": "MT Newswires", "published_at": "2026-07-08T08:06:24+00:00", "published_display": "08 Jul 2026 08:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korro Bio director Formela sells $1.54m in shares", "summary": "Korro Bio director Jean Francois Formela sold approximately $1.54 million worth of shares in early July through a pre-arranged trading plan. These sales occurred after KRRO shares saw a 71% surge over the past six months and coincide with recent analyst upgrades and new pipeline ", "url": "https://www.investing.com/news/insider-trading-news/korro-bio-director-formela-sells-154m-in-shares-93CH-4780443", "source_name": "Investing.com", "published_at": "2026-07-08T07:09:55", "published_display": "08 Jul 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Korro Bio Inc For: 7 July By Investing.com", "summary": "This article announces that Korro Bio Inc. (KRRO) filed a Form 4 for July 7th. A Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the beneficial ownership position of company insiders. The article does no", "url": "https://ca.investing.com/news/stock-market-news/form-4-korro-bio-inc-for-7-july-93CH-4724149", "source_name": "Investing.com Canada", "published_at": "2026-07-07T22:10:25", "published_display": "07 Jul 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Korro Bio For: 6 July By Investing.com", "summary": "This article announces the filing of Form 144 for Korro Bio on July 6th. It briefly mentions the company's stock symbol KRRO and its current performance while providing no further details about the filing itself. The article also includes various market data and other news headli", "url": "https://ca.investing.com/news/stock-market-news/form-144-korro-bio-for-6-july-93CH-4721891", "source_name": "Investing.com Canada", "published_at": "2026-07-07T04:10:30", "published_display": "07 Jul 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korro Bio, Inc. (KRRO) soars 17.6%: Is further upside left in the stock?", "summary": "Korro Bio, Inc. (KRRO) experienced a significant 17.6% surge in its stock price, raising questions about its future growth potential. This movement comes amid broader market trends and the company's recent performance. Investors are now evaluating whether this momentum suggests f", "url": "https://www.msn.com/en-us/health/other/korro-bio-inc-krro-soars-17-6-is-further-upside-left-in-the-stock/ar-AA263PQJ", "source_name": "MSN", "published_at": "2026-07-06T05:40:30", "published_display": "06 Jul 2026 05:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KRRO - Korro Bio Inc Options", "summary": "This article provides a detailed financial overview of Korro Bio Inc (KRRO), including its last close price, market capitalization, income, sales, and various financial ratios. It also lists key performance metrics like insider ownership, institutional ownership, profitability, a", "url": "https://finviz.com/stock?t=KRRO&ta=1&p=d&ty=oc&b=2&r=m1&ov=chain_strike&s=12.5", "source_name": "Finviz", "published_at": "2026-07-04T03:40:50", "published_display": "04 Jul 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korro Bio, Inc.(NasdaqCM: KRRO) added to Russell 2500 Growth Benchmark", "summary": "Korro Bio, Inc. (NasdaqCM: KRRO) has been added to the Russell 2500 Growth Benchmark index. The company specializes in developing genetic medicines based on RNA editing, focusing on diseases like Alpha-1 Antitrypsin Deficiency. Recent news for Korro Bio includes additions to seve", "url": "https://www.marketscreener.com/news/korro-bio-inc-nasdaqcm-krro-added-to-russell-2500-growth-benchmark-ce7f5fdfdd88f322", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T15:57:00", "published_display": "29 Jun 2026 15:57", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korro Bio, Inc.(NasdaqCM: KRRO) added to Russell Microcap Growth Benchmark Index", "summary": "Korro Bio, Inc. (NasdaqCM: KRRO) has been included in the Russell Microcap Growth Benchmark Index. This announcement highlights the company's growing presence in the financial markets. The biopharmaceutical company focuses on developing genetic medicines based on RNA editing for ", "url": "https://www.marketscreener.com/news/korro-bio-inc-nasdaqcm-krro-added-to-russell-microcap-growth-benchmark-index-ce7f5fded08bff23", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T12:42:43", "published_display": "29 Jun 2026 12:42", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korro Bio, Inc.(NasdaqCM: KRRO) added to Russell 3000E Growth Benchmark", "summary": "Korro Bio, Inc. (NasdaqCM: KRRO), a clinical-stage biopharmaceutical company focused on RNA editing for genetic medicines, has been added to the Russell 3000E Growth Benchmark. The company's lead development candidate, KRRO-110, aims to treat Alpha-1 Antitrypsin Deficiency (AATD)", "url": "https://www.marketscreener.com/news/korro-bio-inc-nasdaqcm-krro-added-to-russell-3000e-growth-benchmark-ce7f5fdedf8bff27", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T04:52:00", "published_display": "29 Jun 2026 04:52", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korro Bio, Inc. Actuals & Estimates (NASDAQ:KRRO)", "summary": "This article provides an overview of Korro Bio, Inc. (NASDAQ: KRRO) stock performance, analyst estimates, and financial data. It covers current stock price, historical highs and lows, market capitalization, upcoming earnings dates, and past financial results like revenue and net ", "url": "https://www.tradingview.com/symbols/NASDAQ-KRRO/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-26T00:09:51", "published_display": "26 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KRRO Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Korro Bio, Inc. (KRRO) stock, including analyst price targets, past performance, and key financial data. According to analysts, KRRO has a max estimate of $30.00 and a min estimate of $8.00. The company's current stock price is $12.17, and it ", "url": "https://www.tradingview.com/symbols/NASDAQ-KRRO/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T17:09:51", "published_display": "25 Jun 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atlas Venture sells KRRO common stock in late May\u2013June 2026 (KRRO)", "summary": "Atlas Venture entities recently filed Rule 144 notices detailing proposed and executed sales of Korro Bio, Inc. (KRRO) common stock in May and June 2026. The filings show multiple transactions, including significant sales on June 22 and June 23, 2026, by Atlas Venture Fund XI, L.", "url": "https://www.stocktitan.net/sec-filings/KRRO/144-korro-bio-inc-sec-filing-a3df7f1314ff.html", "source_name": "Stock Titan", "published_at": "2026-06-25T13:42:43", "published_display": "25 Jun 2026 13:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atlas Venture (KRRO) sells 101,579 shares on 06/23/2026, multiple Form 144 entries", "summary": "Korro Bio, Inc. (KRRO) reported multiple sales of its common stock by affiliated holders, Atlas Venture Fund XI, L.P. and Atlas Venture Opportunity Fund II, L.P., through Form 144 filings. The largest listed sale was for 101,579 shares on June 23, 2026, totaling $1,447,785.17. Ot", "url": "https://www.stocktitan.net/sec-filings/KRRO/144-korro-bio-inc-sec-filing-ea3d508274d5.html", "source_name": "Stock Titan", "published_at": "2026-06-25T13:09:55", "published_display": "25 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Korro Bio Inc For: 24 June By Investing.com", "summary": "This article from Investing.com is a regulatory filing update for Korro Bio Inc. It specifically mentions a \"Form 4\" filing dated June 24 and attributes the information to Reuters. The article itself is very brief, serving primarily as a notification about this financial document", "url": "https://au.investing.com/news/stock-market-news/form-4-korro-bio-inc-for-24-june-93CH-4503661", "source_name": "Investing.com Australia", "published_at": "2026-06-25T12:09:51", "published_display": "25 Jun 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korro Bio Insider Sold Shares Worth $2,458,582, According to a Recent SEC Filing", "summary": "An insider at Korro Bio sold shares valued at $2,458,582, as disclosed in a recent SEC filing. The company is a clinical-stage biopharmaceutical firm focused on developing genetic medicines based on RNA editing for both rare and common diseases. Korro Bio's stock performance and ", "url": "https://www.marketscreener.com/news/korro-bio-insider-sold-shares-worth-2-458-582-according-to-a-recent-sec-filing-ce7f5fd8da8ef22d", "source_name": "www.marketscreener.com", "published_at": "2026-06-25T12:09:51", "published_display": "25 Jun 2026 12:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korro Bio director Jean Francois Formela sells $2.45m in shares", "summary": "Korro Bio director Jean Francois Formela sold approximately $2.46 million in company shares across three trading days in late June 2026, executed under a Rule 10b5-1 trading plan. The sales occurred as the stock traded between $13.95 and $14.98, with the current price reflecting ", "url": "https://www.investing.com/news/insider-trading-news/korro-bio-director-jean-francois-formela-sells-245m-in-shares-93CH-4759506", "source_name": "Investing.com", "published_at": "2026-06-25T01:39:53", "published_display": "25 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korro Bio (KRRO) director-affiliated Atlas funds sell 171K shares under 10b5-1 plan", "summary": "Funds affiliated with Korro Bio director Jean Francois Formela, specifically Atlas Venture entities, sold a total of 171,405 shares of Korro Bio common stock through eight open-market transactions. These sales, executed under a pre-arranged Rule 10b5-1 trading plan adopted on Apr", "url": "https://www.stocktitan.net/sec-filings/KRRO/form-4-korro-bio-inc-insider-trading-activity-2201a3e01db5.html", "source_name": "Stock Titan", "published_at": "2026-06-25T01:10:55", "published_display": "25 Jun 2026 01:10", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Korro Bio For: 23 June By Investing.com", "summary": "This article from Investing.com announces the filing of Form 144 for Korro Bio on June 23. It provides limited textual content but is surrounded by extensive financial market data, including various indices, commodity prices, and stock performances. The core message is a direct r", "url": "https://ca.investing.com/news/stock-market-news/form-144-korro-bio-for-23-june-93CH-4704369", "source_name": "Investing.com Canada", "published_at": "2026-06-23T22:20:00", "published_display": "23 Jun 2026 22:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atlas Venture sells KRRO (KRRO) stock \u2014 2,441 and 419 shares reported", "summary": "Atlas Venture has filed a Form 144, indicating proposed sales of Korro Bio, Inc. (KRRO) common stock. Atlas Venture Fund XI intends to sell 2,441 shares for $34,051.95, and Atlas Venture Opportunity Fund II plans to sell 419 shares for $5,845.05, with both sales dated May 28, 202", "url": "https://www.stocktitan.net/sec-filings/KRRO/144-korro-bio-inc-sec-filing-87cae4bbc560.html", "source_name": "Stock Titan", "published_at": "2026-06-23T01:09:21", "published_display": "23 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Korro Bio For: 22 June By Investing.com", "summary": "This article announces the filing of Form 144 for Korro Bio on June 22nd, as reported by Investing.com. It is a brief, technical notification, typical of financial news outlets reporting on regulatory filings. The article also includes stock market data and other news headlines.", "url": "https://ca.investing.com/news/stock-market-news/form-144-korro-bio-for-22-june-93CH-4702061", "source_name": "Investing.com Canada", "published_at": "2026-06-22T21:42:18", "published_display": "22 Jun 2026 21:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korro Bio Inc (KRRO) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "Korro Bio Inc (KRRO) currently holds a price momentum score of 6.96, placing it 183rd in the Biotechnology & Medical Research industry. The stock is trading between resistance at $14.69 and support at $10.58, indicating potential for range-bound swing trading. Technical indicator", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-krro/technical", "source_name": "TradingKey", "published_at": "2026-06-18T22:09:31", "published_display": "18 Jun 2026 22:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Korro Bio (NASDAQ:KRRO) Spend Its Cash Wisely?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korro Bio: RNA Editor Plots Way Back After AATD Study Fail - I'm Holding (NASDAQ:KRRO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPdGlCOHp3dmRfeU9YYWpValZnR1hsdEtBaXptQjhXRVpzMDc4VngxVkctY19HaXZBMEpvdl82S1FPQlBnc09jakxjeFpPX01QQnh4aW5LWW5lc0Z3UDNsLW5CcE5sZV81ZHNzaGxXRHk4ZGhoNm9tcVJwMTJzcWl6UWVTeURfN0xqSmhUNHFNSVlkQ0hCT2o1aEJwWktZSGJ6ZG9vMVpyNl9VdjY0?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "One Korro Bio Insider Raised Stake By 19% In Previous Year", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNVnBZN0JvdHJvMVNBNFFkUDJhYjRmX0QtV1JkV1RIcGtSVjNGUFNYcVU3THZtcjZ5cFZ0ODdDdTdwRk1tbjZBVmFES09jUXFQTnhVbS1UWlpsc3g3RTBfSFpZckMxeGc3RjhYWUJXRWZHeU16X2s0aDlaVl9vdU5kdENzVnZ4MFNuSkdoU3RUcnJJTHA3ak96bw?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korro Bio CEO Ram Aiyar sells $196,672 in company stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQeEJxZU93a3VJYXpqMVpHYXA2cU80b1JhblAwSEpDRG82VVNRMkNpTEJ0ZnNNTFJud0Y0alhxMGlRU19Rd3QtZUExWVJBU3kzUURidEZyOWdFOWswSkxyWmo2djRsN2Q1WEJjUWhRRmx3ZC16ZXQ4T01GYy03bGYtTUtRWGVXR0F6aVF5eVcxS095SW1XV3U5V0NkUEhFUmJzYmlVbzd0ckVPWVl1THFCY3BDWGxkQmxOS2c?oc=5", "source_name": "Investing.com", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korro to Present at the 2026 Jefferies Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/korro-present-2026-jefferies-global-110000963.html", "source_name": "GlobeNewswire", "published_at": "2026-05-27T11:00:00+00:00", "published_display": "27 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/korro-selects-krro-111-development-110000039.html", "source_name": "GlobeNewswire", "published_at": "2026-05-19T11:00:00+00:00", "published_display": "19 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citigroup Initiates Korro Bio at Buy With $21 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/citigroup-initiates-korro-bio-buy-113925505.html", "source_name": "MT Newswires", "published_at": "2026-05-18T11:39:25+00:00", "published_display": "18 May 2026 11:39", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Makes Korro Bio, Inc. (KRRO) a New Buy Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxNcm5ucjVsNDc0bVY0cl9UanNGcDVvXzdWR3hyR3pvVTVadElwSTVEMXctT1M4Tl83NHhDem5MZ2pkR29ld09aVzVveUJUdEVaTzhJSDJ6ekwySlR3TEtsX1l2eGhOMnZsUk0yRWh1ekpQQWIwdEo5ampMQjByUVhiMmVrcTV6MjhqYTRPWDBtMmNOY3c?oc=5", "source_name": "Market source", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investors pour $85M into RNA editor Korro Bio\u2019s genetic disease drugs", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOY3gwamxGdDhtekx2eElRdVhpN2V0UjZuVE9IckdBd1VLY1R0RG92SWtOaFp4RENhd19sbDA4cWVnS3IyazJnQ3hmd1ZJUF9pNi1rRE5rTU9nWWxVSXJfN01wSi1Ub1dWSFNqdTRGVlFmeHFUQmdqQXFPYUttV2VScENObGtpTUtxaUt6SFh3QXlHRFBuNkxFUm5ObTdOZjA5bElVblhwQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korro Announces $85 Million Private Placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxPNG5YTWNheGd2NmtWd3dfUDdqVUNCRi1ScEFKYUtUdTFOcWdYMUF5RUlUMTYwZ2ZRc1NDeTF2QmtnWnBzZlZCRXlla2xZUkpUQ3BBenhxZE9JNkR5R29BZjRxblVIbXk3QlY3UDFHUl9BaWFuNmhsbzI2NzBQT28xZDlnSHFqT0ljcVBz?oc=5", "source_name": "citybiz", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Think Korro Bio (NASDAQ:KRRO) Needs To Drive Business Growth Carefully", "summary": "", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTE0tbWJuYXNnSnR0N29CMzFPUU9xYzNxR1VWZGtBVUlYX0JRX0JLUnR1UFpCdmJ5OV95elIxaU93eXA3NHctUzJ4WlUyNU9VVDJEUkhzekZwdUM4NHVoeFhlTHVWaU0zckdfWktmVjNrSUVYNlIxZXhxWTlEZWduQQ?oc=5", "source_name": "Market source", "published_at": "2026-02-13T08:00:00+00:00", "published_display": "13 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "StockWatch: Korro Craters 81% on Data; Patient Death Sours Analysts on Intellia", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOQ2o1RGhNWXdZNGRISk51aEIyT0s2QWF1dXFkcjZNLXNKdWJ0Y2YzMGxGNnllQUQ1R1ljcjlScWZKMUdJdDEtaFJpNnVHdy1wQzdrekxiR1J2TklJcVVSa3lGUHhIRmR2V1YyZ0FGdE1PaGszdW10Rko2eVJFOHZwUmgta0JVOXgyLUxIQVVrcXQydU1uUXBvUXBzZzJPWTIyeXJ6QV9EYUwyV1g5NTVCRVl0dms1aEs3RTZEREo3S0RaMUNQ?oc=5", "source_name": "Genetic Engineering and Biotechnology News", "published_at": "2025-11-16T08:00:00+00:00", "published_display": "16 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korro Suffers Cacophony of Bad News as Lead Candidate Fails, Novo Pauses RNA Deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNMlZmTTJISHREZktJQ1JQMlh1Sl9rQmY4UjBLWl9CdW5PT001eHpOWHMyMDY5akVfX1VQME5mTDAyRktXQmhmQldpTm4wOHNlVG51MkVjLWlxTkhPMFhoMmNwQi1SQXMyMjZMX196cnl0MThoS21MWWxTdmVFdFprVjJOTFlFT0xkaHpsczEzaFJESG9Ra0lYeGEtYmwweDZESm5iSmxsN0ZSX0tCaVg5bjJha3FHODdlREJYQ0ZfVQ?oc=5", "source_name": "BioSpace", "published_at": "2025-11-13T08:00:00+00:00", "published_display": "13 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Korro Bio, Inc. (KRRO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE1tckc3WngyZmhfUjVnR05kelh6RGlLM0k0NUt0Y01jSkk2dEptb1RndlhRdlZINFBYWnR0TDBSREYxazVYdDBMZURKbU04SlhoTUtTMURIX3B5WmxwNmdQTHNENGhzT1l0WnozMg?oc=5", "source_name": "Zacks Investment Research", "published_at": "2024-04-25T01:06:05+00:00", "published_display": "25 Apr 2024 01:06", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Korro Bio Inc (KRRO) News, Articles, Events & Latest Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTE8xX0dkY0ZFdHNabG0zN213a1JqS1VldWMzVXFtMzRJVnNYMzlZeWxaOEZYRlRCaGtfTGI4b1hESm5tc1I1a3lQU2h4LXNQY1Nu?oc=5", "source_name": "Stocktwits", "published_at": "2023-11-09T02:32:26+00:00", "published_display": "09 Nov 2023 02:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 90, "total_relevant": 50, "sentiment_summary": {"positive": 12, "negative": 4, "neutral": 34, "score": 54, "total": 50, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 17.2, "count": 30}, {"event": "earnings", "label": "Earnings", "weight": 4.4, "count": 10}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "macro", "label": "Macro sensitivity", "weight": 0.55, "count": 1}], "positive_events": 12, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 14.56, "latest_week": "2026-07-10", "one_week_move": 4.0, "four_week_move": 25.4, "twelve_week_move": 1.2, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.948772, "market_dynamics_buy_signal": false, "relative_strength": -28.214869, "fair_value_gap": -54.8, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 42.7169, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+4.0% over one week, +25.4% over four weeks, trend active, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 64, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 9}, {"label": "TradingView", "count": 5}, {"label": "Stock Titan", "count": 5}, {"label": "Investing.com Canada", "count": 4}, {"label": "www.marketscreener.com", "count": 4}, {"label": "Investing.com", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "MT Newswires", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 42}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 30}, {"label": "Earnings", "count": 10}, {"label": "Analyst action", "count": 4}, {"label": "Regulatory and legal", "count": 2}, {"label": "Deals and strategy", "count": 2}, {"label": "Macro sensitivity", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "42", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+4.0% over one week, +25.4% over four weeks, trend active, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"}], "updated_at": "2026-07-16T08:08:33.415221+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}